SCHEMBL3275147

SCHEMBL3275147

CCS(=O)(=O)NCc1c(C(=O)O)n(Cc2cccc3ccccc23)c2ccc(F)cc12

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.48
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 5/20 0.42
MAPT P10636 2/20 0.41
PTGDR2 Q9Y5Y4 5/20 0.41
CYP2C9 P11712 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HASPIN Q8TF76 1/20 0.39
MCL1 Q07820 1/20 0.39
PTGER2 P43116 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3283138 0.92 POLB (0.48) POLBKMT2AMEN1TP53MAPT
SCHEMBL3276283 0.89 MEN1 (0.47) POLBKMT2AMEN1TP53MAPT
SCHEMBL3279487 0.88 POLB (0.48) POLBKMT2AMEN1TP53MAPT
SCHEMBL15512653 0.88 POLB (0.55) POLBKMT2AMEN1TP53MAPT
SCHEMBL3283150 0.88 PER2 (0.46) POLBKMT2AMEN1TP53MAPT
SCHEMBL3274967 0.88 POLB (0.52) POLBKMT2AMEN1TP53MAPT
SCHEMBL3276439 0.86 POLB (0.52) POLBKMT2AMEN1TP53MAPT
SCHEMBL3275938 0.86 POLB (0.53) POLBKMT2AMEN1TP53MAPT
SCHEMBL3283461 0.86 POLB (0.50) POLBKMT2AMEN1TP53MAPT
SCHEMBL3279412 0.84 POLB (0.48) POLBKMT2AMEN1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966134-B1 NOVEL FUSED PYRROLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-12 EP disclosed
US-7696240-B2 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-04-13 US disclosed
US-7696240-B2 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-04-13 US disclosed
US-7696240-B2 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-04-13 US disclosed
EP-1966134-A1 NOVEL FUSED PYRROLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
WO-2007068621-A1 NOVEL FUSED PYRROLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-21 WO disclosed
WO-2007068621-A1 NOVEL FUSED PYRROLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-21 WO disclosed
US-20070142452-A1 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. 2007-06-21 US disclosed
US-20070142452-A1 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. 2007-06-21 US disclosed
US-20070142452-A1 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142452-A1 Fused pyrrole derivatives CMA1, PREP, CPA3 POLB 1631/4885KMT2A 3786/4885MEN1 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.